Research interests include clinical and translational research in new drug development, gastrointestinal and genito-urinary malignancies. Dr. Knox is also the Principal Investigator of trials in biliary, hepatocellular, esophageal and renal cell cancers.
Health utility scores from EQ-5D and health-related quality of life in patients with esophageal cancer: a real-world cross-sectional study.
Dis Esophagus. 2018 Jun 14;:
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
Lancet Oncol. 2018 Jun 01;:
Cancer Discov. 2018 May 31;:
Prognosis of patients with hepatocellular carcinoma treated with sorafenib: a comparison of five models in a large Canadian database.
Cancer Med. 2018 May 15;:
The ongoing challenge of large anal cancers: prospective long term outcomes of intensity-modulated radiation therapy with concurrent chemotherapy.
Oncotarget. 2018 Apr 17;9(29):20439-20450
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.
Lancet Oncol. 2018 Apr 03;:
Neoadjuvant hyperfractionated chemoradiation and liver transplantation for unresectable perihilar cholangiocarcinoma in Canada.
J Surg Oncol. 2018 Feb;117(2):213-219
Comparison of Practice Guidelines, BRCAPRO, and Genetic Counselor Estimates to Identify Germline BRCA1 and BRCA2 Mutations in Pancreatic Cancer.
J Genet Couns. 2018 Feb 13;:
Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.
Ann Oncol. 2018 Jan 29;:
Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer - Early Results from the COMPASS Trial.
Clin Cancer Res. 2017 Dec 29;:
Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre
Associate Professor, Department of Medicine, University of Toronto
Chair, Kidney Disease Oriented Group, National Cancer Institute of Canada
Chair, Hepatobiliary Disease Oriented Group, National Cancer Institute of Canada